In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eli Lilly to buy Avid for $300mm up front plus earn-outs

Executive Summary

Eli Lilly & Co. has agreed to pay $300mm up front to acquire privately held Avid Radiopharmaceuticals Inc., a developer of molecular imaging agents that detect and monitor various diseases.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register